Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
View Imugene CEO Leslie Chong presenting at the 9th Annual Biotech Showcase, San Francisco 9 Jan 17 (click here) and being interviewed on Edison TV Executive Interviews Mar 17 (click here). View Nov 2017 Imugene Immuno-Oncology Expert Briefing (click here) featuring Imugene's NED Dr Axel Hoos, SAB Head Prof. Dr. Christoph Zielinski and CSO Prof. Dr. Ursula Wiedermann.
Our lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.
Click here to view latest Imugene Fact Sheet
Click here to view video that introduces HER-Vaxx and explains how it works
Click here to view Imugene's current share price
Click here to view Leslie Chong interview with Medicalresearch.com "Imugene Building Pipeline of B Cell Peptide Cancer Vaccines".
Click here to read "What's Hot & What's Not in Immuno-Oncology Licensing. Dr Axel Hoos is interviewed as part of an expert panel.
HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer. Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.
HER-Vaxx has shown success in stimulating the production of lifesaving HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. Its further development is directed towards providing a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which have become one of the world’s bestselling cancer drugs with annual sales in excess of $US6.7 billion (Roche Investor Update 30/1/17).
Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.
Imugene is also building a pipeline of small molecule immuno-oncology drugs. Arginine is a critical amino acid for the health of cancer fighting T-cells and depletion of it limits the effectiveness of T-cells to fight tumours. We are leveraging our core expertise in tumor biology and medicinal chemistry to develop small molecule selective arginine modulators.
Imugene’s corporate headquarters are located in Melbourne, Australia with most of the scientific team in Vienna, Austria.